A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A

Elizabeth Guardiani, Babak Sadoughi, Andrew Blitzer, David Sirois

Research output: Contribution to journalArticle

Abstract

Objectives To review the current data for the use of Botulinum toxin type A (BoNT-A) in trigeminal neuralgia (TN) and to describe the preferred injection technique of BoNT-A in TN. To propose a new treatment paradigm for TN incorporating the use BoNT-A. Data Sources MEDLINE and Google Scholar databases. Review Methods The current data on BoNT-A for TN were reviewed and analyzed for outcomes. Results Seven studies examining the use of BoNT-A were identified: Two randomized double-blind, placebo-controlled studies and five prospective case series. All studies found BoNT-A to be an effective treatment in the majority of patients; and the results of the two randomized double-blind placebo-controlled study showed significant benefit over placebo. The majority of studies used an intradermal or subcutaneous injection technique. The most common side effect was transient facial paresis. Conclusions BoNT-A offers a safe, effective, local treatment for TN that is nonablative in nature. BoNT-A should be considered in patients who have failed, become refractory to, or are unable to tolerate first-line pharmacologic treatments. Level of Evidence N/A.

Original languageEnglish (US)
Pages (from-to)413-417
Number of pages5
JournalLaryngoscope
Volume124
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Trigeminal Neuralgia
Type A Botulinum Toxins
Placebos
Therapeutics
Intradermal Injections
Facial Paralysis
Information Storage and Retrieval
Subcutaneous Injections
MEDLINE
Databases
Prospective Studies
Injections

Keywords

  • Botulinum toxin
  • Facial pain
  • trigeminal neuralgia

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Medicine(all)

Cite this

A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A. / Guardiani, Elizabeth; Sadoughi, Babak; Blitzer, Andrew; Sirois, David.

In: Laryngoscope, Vol. 124, No. 2, 02.2014, p. 413-417.

Research output: Contribution to journalArticle

Guardiani, Elizabeth ; Sadoughi, Babak ; Blitzer, Andrew ; Sirois, David. / A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A. In: Laryngoscope. 2014 ; Vol. 124, No. 2. pp. 413-417.
@article{0aa85cba160a4fae8e3ce45f1e958633,
title = "A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A",
abstract = "Objectives To review the current data for the use of Botulinum toxin type A (BoNT-A) in trigeminal neuralgia (TN) and to describe the preferred injection technique of BoNT-A in TN. To propose a new treatment paradigm for TN incorporating the use BoNT-A. Data Sources MEDLINE and Google Scholar databases. Review Methods The current data on BoNT-A for TN were reviewed and analyzed for outcomes. Results Seven studies examining the use of BoNT-A were identified: Two randomized double-blind, placebo-controlled studies and five prospective case series. All studies found BoNT-A to be an effective treatment in the majority of patients; and the results of the two randomized double-blind placebo-controlled study showed significant benefit over placebo. The majority of studies used an intradermal or subcutaneous injection technique. The most common side effect was transient facial paresis. Conclusions BoNT-A offers a safe, effective, local treatment for TN that is nonablative in nature. BoNT-A should be considered in patients who have failed, become refractory to, or are unable to tolerate first-line pharmacologic treatments. Level of Evidence N/A.",
keywords = "Botulinum toxin, Facial pain, trigeminal neuralgia",
author = "Elizabeth Guardiani and Babak Sadoughi and Andrew Blitzer and David Sirois",
year = "2014",
month = "2",
doi = "10.1002/lary.24286",
language = "English (US)",
volume = "124",
pages = "413--417",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A

AU - Guardiani, Elizabeth

AU - Sadoughi, Babak

AU - Blitzer, Andrew

AU - Sirois, David

PY - 2014/2

Y1 - 2014/2

N2 - Objectives To review the current data for the use of Botulinum toxin type A (BoNT-A) in trigeminal neuralgia (TN) and to describe the preferred injection technique of BoNT-A in TN. To propose a new treatment paradigm for TN incorporating the use BoNT-A. Data Sources MEDLINE and Google Scholar databases. Review Methods The current data on BoNT-A for TN were reviewed and analyzed for outcomes. Results Seven studies examining the use of BoNT-A were identified: Two randomized double-blind, placebo-controlled studies and five prospective case series. All studies found BoNT-A to be an effective treatment in the majority of patients; and the results of the two randomized double-blind placebo-controlled study showed significant benefit over placebo. The majority of studies used an intradermal or subcutaneous injection technique. The most common side effect was transient facial paresis. Conclusions BoNT-A offers a safe, effective, local treatment for TN that is nonablative in nature. BoNT-A should be considered in patients who have failed, become refractory to, or are unable to tolerate first-line pharmacologic treatments. Level of Evidence N/A.

AB - Objectives To review the current data for the use of Botulinum toxin type A (BoNT-A) in trigeminal neuralgia (TN) and to describe the preferred injection technique of BoNT-A in TN. To propose a new treatment paradigm for TN incorporating the use BoNT-A. Data Sources MEDLINE and Google Scholar databases. Review Methods The current data on BoNT-A for TN were reviewed and analyzed for outcomes. Results Seven studies examining the use of BoNT-A were identified: Two randomized double-blind, placebo-controlled studies and five prospective case series. All studies found BoNT-A to be an effective treatment in the majority of patients; and the results of the two randomized double-blind placebo-controlled study showed significant benefit over placebo. The majority of studies used an intradermal or subcutaneous injection technique. The most common side effect was transient facial paresis. Conclusions BoNT-A offers a safe, effective, local treatment for TN that is nonablative in nature. BoNT-A should be considered in patients who have failed, become refractory to, or are unable to tolerate first-line pharmacologic treatments. Level of Evidence N/A.

KW - Botulinum toxin

KW - Facial pain

KW - trigeminal neuralgia

UR - http://www.scopus.com/inward/record.url?scp=84892910373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892910373&partnerID=8YFLogxK

U2 - 10.1002/lary.24286

DO - 10.1002/lary.24286

M3 - Article

VL - 124

SP - 413

EP - 417

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 2

ER -